Affinity Asset Advisors, LLC XENE — XENON PHARMACEUTICALS INC

Ownership history in Affinity Asset Advisors, LLC  ·  17 quarters on record

AI Ownership Summary

Affinity Asset Advisors, LLC reported XENON PHARMACEUTICALS INC (XENE) in 17 quarterly 13F filings from 2023 Q4 through 2026 Q1. Peak portfolio weight reached 6.15% in 2024 Q3. The latest visible filing shows XENE at 5.03% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this XENE ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Affinity Asset Advisors, LLC's position in XENON PHARMACEUTICALS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

XENE was reported at 5.03% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
6.15% in 2024 Q3

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

XENE stock page Affinity Asset Advisors, LLC fund profile Affinity Asset Advisors, LLC full holdings
How Affinity Asset Advisors, LLC held XENE — position size vs. price
% of Fund (quarterly)    XENE price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 10 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 ADDED — — — 1,675,000 +425,000 +34.0% 5.03% $97.4M 2026-05-14 $56.00
2025 Q4 REDUCED 10.7% +29.7% ❌ 1,250,000 -150,000 -10.7% 3.19% $56.0M 2026-02-13 $41.48
2025 Q3 ADDED — — — 1,400,000 +300,000 +27.3% 4.90% $56.2M 2025-11-13 $40.04
2025 Q2 REDUCED 17.2% +24.8% ❌ 1,100,000 -228,175 -17.2% 4.70% $34.4M 2025-08-13 $37.67
2025 Q1 ADDED — — — 1,328,175 +166,938 +14.4% 4.25% $44.6M 2025-05-14 $29.74
2024 Q4 ADDED — — — 1,161,237 +17,216 +1.5% 6.10% $45.5M 2025-02-13 $39.26
2024 Q3 ADDED — — — 1,144,021 +149,794 +15.1% 6.15% $45.0M 2024-11-13 $41.97
2024 Q2 ADDED — — — 994,227 +156,840 +18.7% 4.47% $38.8M 2024-08-14 $38.70
2024 Q1 ADDED — — — 837,387 +377,387 +82.0% 4.46% $36.0M 2024-05-14 $40.58
2023 Q4 ADDED — — — 460,000 +159,562 +53.1% 3.87% $21.2M 2024-02-13 $48.06
7 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

🏢 Other funds also holding XENE

As of 2026 Q1 — sorted by position size

Trails Edge Capital Partners, LP 5.86% Caligan Partners LP 3Y 5.39% First Turn Management, LLC 5.11% NEXTBio Capital Management LP 4.95% TLS Advisors LLC 3Y 4.27% Foresite Capital Management IV, LLC 3Y 7Y 3.92% DAFNA Capital Management LLC 3Y 7Y 3.32% Avoro Capital Advisors LLC 3Y 7Y 3.31% Octagon Capital Advisors LP 3Y 3.15% Parkman Healthcare Partners LLC 3Y 2.98%

FAQ About Affinity Asset Advisors, LLC and XENE

These are the practical questions this page is built to answer before you even open the full history table.

How long has Affinity Asset Advisors, LLC reported owning XENE?

Affinity Asset Advisors, LLC reported XENE across 10 quarterly 13F filings, from 2023 Q4 through 2026 Q1.

What was the largest reported XENE position in Affinity Asset Advisors, LLC's portfolio?

The largest reported portfolio weight for XENE was 6.15% in 2024 Q3.

What is the latest reported XENE position on this page?

The most recent filing on this page is 2026 Q1, when Affinity Asset Advisors, LLC reported 1,675,000 shares, equal to 5.03% of portfolio, with an estimated market value of $97.4M.

What does the chart on this XENE ownership page compare?

The chart compares Affinity Asset Advisors, LLC's quarterly XENE portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Affinity Asset Advisors, LLC time their XENE position?

Based on 13F filing dates vs. subsequent XENE price moves, Affinity Asset Advisors, LLC correctly timed 5 out of 16 reported position changes (31%). The annualised alpha on XENE relative to SPY over the holding period was +1.1%.

← Back to Affinity Asset Advisors, LLC Holdings